Please login to the form below

Not currently logged in
Email:
Password:

EASD: Novo’s degludec shows promise

Novo Nordisk's investigational basal insulin degludec is effective when used under stressed frequencies of injection in patients with type 2 diabetes, according to a study presented at the European Association for the Study of Diabetes meeting

Novo Nordisk's investigational basal insulin degludec is effective when used under stressed frequencies of injection in patients with type 2 diabetes.

Presenting study data at the European Association for the Study of Diabetes (EASD) meeting in Lisbon, Portugal, the Danish pharmaceutical company said degludec showed reductions in blood sugar levels of patients with type 2 diabetes, even when doses were given once-daily up to 40 hours apart.

The comparator insulin glargine was given to patients once-daily at a specific time of day according to its label instructions.

Professor David Matthews, Professor of Diabetic Medicine at the University of Oxford, UK, said the results were of potential benefit for patients as they would be able to sustain low blood sugar levels even if they missed an injection the previous day.

Young people with diabetes; patients in nursing homes; and carers who look after partners and family members with diabetes were cited by Matthews as groups who could often miss a daily insulin injection.

Overall rates of hypoglycaemia were 3.6 and 3.5 episodes per person per year for insulin degludec and insulin glargine respectively with rates of night-time hypoglycaemia being 0.6 and 0.7 episodes per person per year respectively.

The weight gain reported in patients taking degludec was more than in the glargine arm, but the difference was not significant according to Novo.

Novo's chief science officer Mads Krogsgaard Thomsen said that the company expects to file for regulatory approval of degludec in Europe and the US in the next few months.

15th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

The truth is out there: Patients first
Patient centricity, patient focus, patients first – words that are on everyone’s lips these days. But what do they really mean? Where does the patient voice fit in? And what...
mHealth: The revolution will not be digital
Could mHealth, which has been growing exponentially in recent years, be the answer we have been looking for to address our population health challenge? Could mHealth save healthcare?...
Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....

Infographics